These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 16835371)

  • 21. Mechanism of the dopamine-releasing actions of amphetamine and cocaine: plasmalemmal dopamine transporter versus vesicular monoamine transporter.
    Pifl C; Drobny H; Reither H; Hornykiewicz O; Singer EA
    Mol Pharmacol; 1995 Feb; 47(2):368-73. PubMed ID: 7870046
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Melatonin attenuates the amphetamine-induced decrease in vesicular monoamine transporter-2 expression in postnatal rat striatum.
    Mukda S; Vimolratana O; Govitrapong P
    Neurosci Lett; 2011 Jan; 488(2):154-7. PubMed ID: 21078367
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Measurement of plasmalemmal dopamine transport, vesicular dopamine transport, and K(+)-stimulated dopamine release in frozen rat brain tissue.
    Volz TJ; Farnsworth SJ; Hanson GR; Fleckenstein AE
    J Neurosci Methods; 2009 Jun; 180(2):317-20. PubMed ID: 19464519
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Methylphenidate alters vesicular monoamine transport and prevents methamphetamine-induced dopaminergic deficits.
    Sandoval V; Riddle EL; Hanson GR; Fleckenstein AE
    J Pharmacol Exp Ther; 2003 Mar; 304(3):1181-7. PubMed ID: 12604695
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Carrier-dependent and Ca(2+)-dependent 5-HT and dopamine release induced by (+)-amphetamine, 3,4-methylendioxymethamphetamine, p-chloroamphetamine and (+)-fenfluramine.
    Crespi D; Mennini T; Gobbi M
    Br J Pharmacol; 1997 Aug; 121(8):1735-43. PubMed ID: 9283711
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Kinetic analysis of developmental changes in vesicular monoamine transporter-2 function.
    Volz TJ; Hanson GR; Fleckenstein AE
    Synapse; 2006 Nov; 60(6):474-7. PubMed ID: 16897727
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fluoroalkyl derivatives of dihydrotetrabenazine as positron emission tomography imaging agents targeting vesicular monoamine transporters.
    Goswami R; Ponde DE; Kung MP; Hou C; Kilbourn MR; Kung HF
    Nucl Med Biol; 2006 Aug; 33(6):685-94. PubMed ID: 16934687
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vivo measures of dopaminergic radioligands in the rat brain: equilibrium infusion studies.
    Kilbourn MR; Sherman PS; Kuszpit K
    Synapse; 2002 Mar; 43(3):188-94. PubMed ID: 11793424
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dopamine D2 receptor activation increases vesicular dopamine uptake and redistributes vesicular monoamine transporter-2 protein.
    Truong JG; Newman AH; Hanson GR; Fleckenstein AE
    Eur J Pharmacol; 2004 Nov; 504(1-2):27-32. PubMed ID: 15507217
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vesicular monoamine transporter-2 and aromatic L-amino acid decarboxylase gene therapy prevents development of motor complications in parkinsonian rats after chronic intermittent L-3,4-dihydroxyphenylalanine administration.
    Lee WY; Lee EA; Jeon MY; Kang HY; Park YG
    Exp Neurol; 2006 Jan; 197(1):215-24. PubMed ID: 16269145
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of a novel, inhibitory action of amiodarone on vesicular monoamine transport.
    Haikerwal D; Dart AM; Little PJ; Kaye DM
    J Pharmacol Exp Ther; 1999 Feb; 288(2):834-7. PubMed ID: 9918596
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transport mechanisms in acetylcholine and monoamine storage.
    Parsons SM
    FASEB J; 2000 Dec; 14(15):2423-34. PubMed ID: 11099460
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis and evaluation of 2-amino-dihydrotetrabenzine derivatives as probes for imaging vesicular monoamine transporter-2.
    Zhu L; Liu J; Kung HF
    Bioorg Med Chem Lett; 2009 Sep; 19(17):5026-8. PubMed ID: 19632829
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Amphetamine augments vesicular dopamine release in the dorsal and ventral striatum through different mechanisms.
    Avelar AJ; Juliano SA; Garris PA
    J Neurochem; 2013 May; 125(3):373-85. PubMed ID: 23406303
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activity-dependent vesicular monoamine transporter-mediated depletion of the nucleus supports somatic release by serotonin neurons.
    Colgan LA; Putzier I; Levitan ES
    J Neurosci; 2009 Dec; 29(50):15878-87. PubMed ID: 20016104
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular Mechanisms of Amphetamines.
    Reith MEA; Gnegy ME
    Handb Exp Pharmacol; 2020; 258():265-297. PubMed ID: 31286212
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of monoamine transporters in mediating psychostimulant effects.
    Riddle EL; Fleckenstein AE; Hanson GR
    AAPS J; 2005 Dec; 7(4):E847-51. PubMed ID: 16594636
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Psychostimulant-induced alterations in vesicular monoamine transporter-2 function: neurotoxic and therapeutic implications.
    Fleckenstein AE; Volz TJ; Hanson GR
    Neuropharmacology; 2009; 56 Suppl 1(Suppl 1):133-8. PubMed ID: 18662707
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Release of met-enkephalin from rat striatal slices: effect of amphetamine and fipexide.
    Lucchi L; Govoni S; Spano PF; Trabucchi M
    Brain Res; 1986 Nov; 398(1):212-4. PubMed ID: 2879607
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tyramine synthesis, vesicular packaging, and the SNARE complex function coordinately in astrocytes to regulate Drosophila alcohol sedation.
    Lee KM; Talikoti A; Shelton K; Grotewiel M
    Addict Biol; 2021 Jul; 26(4):e13019. PubMed ID: 33538092
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.